undamentalytics Newsletter
Sign in

Benitec Biopharma Inc. (BNTC) stock

Add to watchlist

Add holding +

NASDAQ: BNTC Nasdaq Biotechnology Next results ~November 12, 2026

Benitec Biopharma Inc. is a US-listed company in the biotechnology industry. Its financial year ends in June.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders3 buying, 0 selling14 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds47 adding, 32 cuttingOf 14 active managers that changed their stake, 9 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Benitec Biopharma Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Revenue shrinking. Revenue fell 100.0% over the last 12 months.
  • Loss-making. Operating margin is -307028.6%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 278691.8 points on a year ago.
  • Burning cash. Free cash flow was -288642.9% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 7185.7% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 52.6% in a year.

Latest results: FY2026 Q3

Filed May 14, 2026
Earnings per share
-$0.26 against an average estimate of -$0.27: beat by 1.9%
Share reaction
-9.4% in the first session after the results on September 14, 2026, against -0.9% for the S&P 500
Next report
November 12, 2026

Benitec Biopharma's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.9%
  • 1 week-1.2%
  • 1 month-5.5%
  • This year-37.0%
  • 1 year-48.1%
  • 5 years-86.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$0
EPS (TTM, diluted)
$-0.82

Growth

Revenue growth
−100.0%
Change in growth rate
+0.0 pts
Share count change
+52.6%

Earnings

Last results
September 14, 2026
Next results (est.)
December 14, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Benitec Biopharma Inc. valuation models and calculator

No model value for Benitec Biopharma Inc. at the moment. Current status: data-quality checks not passed. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, after the close. Analysts expect revenue of $0 for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.22 −25% — 0%
Next −$1.43 −17% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +6.8% on 90 days ago. In the last 30 days, 0 analysts raised Benitec Biopharma Inc.'s forecast and 3 cut it.

Consensus EPS forecast Benitec Biopharma Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.14 Current fiscal year, 60 days ago: −$1.11 Current fiscal year, 30 days ago: −$1.20 Current fiscal year, 7 days ago: −$1.18 Current fiscal year, Now: −$1.22 −$1.22 Next fiscal year, 90 days ago: −$1.22 Next fiscal year, 60 days ago: −$1.19 Next fiscal year, 30 days ago: −$1.32 Next fiscal year, 7 days ago: −$1.32 Next fiscal year, Now: −$1.43 −$1.43

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.14−$1.22
60 days ago −$1.11−$1.19
30 days ago −$1.20−$1.32
7 days ago −$1.18−$1.32
Now −$1.22−$1.43

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.27 −$0.26 +1.9%
Mar 2026 −$0.28 −$0.24 +12.7%
Dec 2025 −$0.23 −$0.26 −15.0%
Sept 2025 −$0.36 −$0.22 +38.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

8 analysts, Oct 2026
Buy8100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026268
  2. Sep 2026167
  3. Aug 2026167
  4. Jul 2026167

Counts of recommendations published by analysts covering Benitec Biopharma Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
10.0%
of tradable shares
Days to cover
9.77
at average volume
Short interest, 1 month
−9%
to October 15, 2026
Held by institutions
96%
of shares
Held by insiders
0.2%
of shares
Employees
24
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
BNTC−13%−94%+12%+291%+7%−37%
Industry peers (median)−36%−56%−18%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
BNTC42%25%50%58%67%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
BNTC−72%−96%−69%−40%−36%−42%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from November 3, 2015 to August 8, 2023. Getting back needed a 78953% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$8.11 – $15.86
From 52-week high
−46.5%
vs 50-day average
−17.5%
vs 200-day average
−26.3%
Volatility (1 year)
60%
Beta vs S&P 500
1.55

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±5.9%
After a week
8 up, 4 down
typical move ±8.0%
After a month
7 up, 5 down
typical move ±24.4%
Results releasedNext dayS&P 500 next day5 days21 days
September 14, 2026 −9.4% −0.9% −10.7% −29.2%
May 14, 2026 −1.4% −0.4% −2.5% −2.7%
February 12, 2026 −10.9% −1.5% −8.7% +3.1%
November 14, 2025 +2.9% −0.9% +0.8% −5.6%
September 22, 2025 −1.7% −0.1% +4.0% +17.9%
May 14, 2025 +2.4% +0.6% +3.7% +25.0%
February 14, 2025 +16.1% +0.3% +8.6% +60.0%
November 14, 2024 +2.3% −1.9% −2.3% +20.5%
September 26, 2024 +4.9% +0.3% +11.5% +24.9%
May 13, 2024 −8.9% +0.5% +13.2% −19.2%
February 13, 2024 −1.8% −0.5% +27.3% +81.4%
November 13, 2023 +7.6% +1.8% +2.9% −3.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Benitec Biopharma Inc.
$0 $20K $40K $60K $80K FY22 Q4 FY23 Q3 FY24 Q2 FY25 Q3 Revenue (TTM), FY22 Q4: $73K Revenue (TTM), FY23 Q1: $73K Revenue (TTM), FY23 Q2: $62K Revenue (TTM), FY23 Q3: $68K Revenue (TTM), FY23 Q4: $75K Revenue (TTM), FY24 Q1: $75K Revenue (TTM), FY24 Q2: $61K Revenue (TTM), FY24 Q3: $7K Revenue (TTM), FY24 Q4: $0 Revenue (TTM), FY25 Q1: $0 Revenue (TTM), FY25 Q2: $0 Revenue (TTM), FY25 Q3: $0 $0

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY22 Q4 $73K
FY23 Q1 $73K
FY23 Q2 $62K
FY23 Q3 $68K
FY23 Q4 $75K
FY24 Q1 $75K
FY24 Q2 $61K
FY24 Q3 $7K
FY24 Q4 $0
FY25 Q1 $0
FY25 Q2 $0
FY25 Q3 $0
Revenue growth, TTM YoY Benitec Biopharma Inc.
-500% 0% 500% 1000% 1500% 2000% FY22 Q4 FY23 Q3 FY24 Q2 FY25 Q3 Revenue growth, TTM YoY, FY22 Q4: 23.7% Revenue growth, TTM YoY, FY23 Q1: 1725.0% Revenue growth, TTM YoY, FY23 Q2: 121.4% Revenue growth, TTM YoY, FY23 Q3: -9.3% Revenue growth, TTM YoY, FY23 Q4: 2.7% Revenue growth, TTM YoY, FY24 Q1: 2.7% Revenue growth, TTM YoY, FY24 Q2: -1.6% Revenue growth, TTM YoY, FY24 Q3: -89.7% Revenue growth, TTM YoY, FY24 Q4: -100.0% Revenue growth, TTM YoY, FY25 Q1: -100.0% Revenue growth, TTM YoY, FY25 Q2: -100.0% Revenue growth, TTM YoY, FY25 Q3: -100.0% -100.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY22 Q4 23.7%
FY23 Q1 1725.0%
FY23 Q2 121.4%
FY23 Q3 -9.3%
FY23 Q4 2.7%
FY24 Q1 2.7%
FY24 Q2 -1.6%
FY24 Q3 -89.7%
FY24 Q4 -100.0%
FY25 Q1 -100.0%
FY25 Q2 -100.0%
FY25 Q3 -100.0%
Operating margin (TTM) Benitec Biopharma Inc.
-400000% -300000% -200000% -100000% 0% FY21 Q4 FY22 Q3 FY23 Q2 FY24 Q3 Operating margin (TTM), FY21 Q4: -23045.8% Operating margin (TTM), FY22 Q1: -393225.0% Operating margin (TTM), FY22 Q2: -61803.6% Operating margin (TTM), FY22 Q3: -22629.3% Operating margin (TTM), FY22 Q4: -24458.9% Operating margin (TTM), FY23 Q1: -24127.4% Operating margin (TTM), FY23 Q2: -29658.1% Operating margin (TTM), FY23 Q3: -28336.8% Operating margin (TTM), FY23 Q4: -25441.3% Operating margin (TTM), FY24 Q1: -27166.7% Operating margin (TTM), FY24 Q2: -35560.7% Operating margin (TTM), FY24 Q3: -307028.6% -307028.6%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY21 Q4 -23045.8%
FY22 Q1 -393225.0%
FY22 Q2 -61803.6%
FY22 Q3 -22629.3%
FY22 Q4 -24458.9%
FY23 Q1 -24127.4%
FY23 Q2 -29658.1%
FY23 Q3 -28336.8%
FY23 Q4 -25441.3%
FY24 Q1 -27166.7%
FY24 Q2 -35560.7%
FY24 Q3 -307028.6%
FCF margin (TTM) Benitec Biopharma Inc.
-400000% -300000% -200000% -100000% 0% FY21 Q4 FY22 Q3 FY23 Q2 FY24 Q3 FCF margin (TTM), FY21 Q4: -22123.7% FCF margin (TTM), FY22 Q1: -369950.0% FCF margin (TTM), FY22 Q2: -52292.9% FCF margin (TTM), FY22 Q3: -21413.3% FCF margin (TTM), FY22 Q4: -21797.3% FCF margin (TTM), FY23 Q1: -21460.3% FCF margin (TTM), FY23 Q2: -29298.4% FCF margin (TTM), FY23 Q3: -27605.9% FCF margin (TTM), FY23 Q4: -24016.0% FCF margin (TTM), FY24 Q1: -24725.3% FCF margin (TTM), FY24 Q2: -29616.4% FCF margin (TTM), FY24 Q3: -288642.9% -288642.9%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY21 Q4 -22123.7%
FY22 Q1 -369950.0%
FY22 Q2 -52292.9%
FY22 Q3 -21413.3%
FY22 Q4 -21797.3%
FY23 Q1 -21460.3%
FY23 Q2 -29298.4%
FY23 Q3 -27605.9%
FY23 Q4 -24016.0%
FY24 Q1 -24725.3%
FY24 Q2 -29616.4%
FY24 Q3 -288642.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Jun 2019 2020 Jun 2020 2021 Jun 2021 2022 Jun 2022 2023 Jun 2023 2024 Jun 2024 LTM Mar 2025
Income
Revenue 12 0 0 0 0 0 0
EBITDA 3 −8 −13 −18 −19 −22 −37
Operating income 3 −8 −14 −18 −19 −22 −37
Net income 3 −8 −14 −18 −20 −22 −34
Diluted EPS $0.05 −$0.01 −$0.21 −$0.29 −$0.32 −$1.22 —
Growth (year on year)
Revenue — −99.2% −42.2% +23.7% +2.7% −100.0% −100.0%
EBITDA — −395.2% — — — — —
Operating income — −420.6% — — — — —
Net income — −417.1% — — — — —
Diluted EPS — −115.6% — — — — —
Margins
EBITDA margin 22.5% <−999% <−999% <−999% <−999% — —
Operating margin 21.2% <−999% <−999% <−999% <−999% — —
Net margin 21.4% <−999% <−999% <−999% <−999% — —
Free-cash-flow margin 36.0% <−999% <−999% <−999% <−999% — —
Cash flow
Cash from operations 5 −8 −13 −16 −18 −19 −19
Capital spending 0 0 0 0 0 0 0
Free cash flow 4 −8 −13 −16 −18 −20 −19
Stock-based pay 1 0 1 1 0 1 12
Free cash flow after stock pay 4 −8 −14 −17 −18 −20 −30
Balance sheet
Cash 16 10 20 4 2 51 104
Total debt 0 0 0 0 0 0 0
Net debt (negative = net cash) −16 −10 −20 −4 −2 −51 −104
Diluted shares 53m 64m 67m 64m 61m 18m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

Diluted share count
+52.6%
year over year

Who owns it

Funds buying and selling
Reported value
$464M
Institutions reporting
87
Shares held vs prior quarter
▲ 6.7%
Positions opened / closed
11 / 10

Top buyers and sellers, Q2 2026: 47 institutions bought and 32 sold ; the biggest buyer was Nantahala Capital Management, LLC (+1.5M shares) and the biggest seller Longaeva Partners L.P (−110K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Montanova Capital, LLC $155M 11.5M 33.3% 0.0%
Nantahala Capital Management, LLC $39.8M 3.0M 8.6% ▲ 107.0%
Jupiter Topco LLC $33.1M 2.5M 7.1% —
Franklin Resources Inc $32.3M 2.4M 7.0% ▲ 1.5%
Adage Capital Partners Gp, L.L.C. $28.4M 2.1M 6.1% 0.0%
RA Capital Management, L.P. $24.8M 1.9M 5.3% 0.0%
Blackrock, Inc. $18.8M 1.4M 4.1% ▲ 18.7%
Simplify Asset Management Inc. $13.5M 1.0M 2.9% ▲ 78.8%
Vanguard Capital Management LLC $12.8M 955K 2.8% ▲ 2.5%
Infinitum Asset Management, LLC $12.3M 923K 2.7% 0.0%
Millennium Management LLC $12.3M 921K 2.7% ▲ 41.3%
Alyeska Investment Group, L.P. $10M 750K 2.2% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Benitec Biopharma Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $22.4M 14 trades by 3 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $22.4M net buying
Insider Date Trade Shares Price Value
Cowen Aaron Director December 29, 2025 Buy 11,587 $13.44 $155,729
Cowen Aaron Director December 29, 2025 Buy 65,800 $13.44 $884,352
Cowen Aaron Director December 26, 2025 Buy 2,516 $13.10 $32,960
Cowen Aaron Director December 26, 2025 Buy 14,320 $13.10 $187,592
Cowen Aaron Director December 23, 2025 Buy 42,600 $12.85 $547,410
Cowen Aaron Director December 23, 2025 Buy 7,400 $12.85 $95,090
Averill Madison Master Fund, Ltd. 10% owner December 22, 2025 Buy 2,892 $12.08 $34,935
Averill Madison Master Fund, Ltd. 10% owner December 22, 2025 Buy 16,650 $12.08 $201,132
Averill Madison Master Fund, Ltd. 10% owner December 19, 2025 Buy 13,950 $11.48 $160,146
Averill Madison Master Fund, Ltd. 10% owner December 19, 2025 Buy 2,434 $11.48 $27,942
Averill Madison Master Fund, Ltd. 10% owner December 18, 2025 Buy 1,515 $11.24 $17,029
Averill Madison Master Fund, Ltd. 10% owner December 18, 2025 Buy 8,700 $11.24 $97,788

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around December 14, 2026 estimated from the company's past filing pattern, not announced

  • September 14, 2026
  • May 14, 2026
  • February 12, 2026
  • November 14, 2025
  • September 22, 2025
  • May 14, 2025

Recent SEC filings

Data status

When each part of this page on Benitec Biopharma Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Benitec Biopharma Inc. in brief

What does Benitec Biopharma Inc. do?
Benitec Biopharma Inc. is a US-listed company in the biotechnology industry. Its financial year ends in June.
What is Benitec Biopharma Inc.'s stock ticker?
Benitec Biopharma Inc. trades under the ticker BNTC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Benitec Biopharma Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Benitec Biopharma Inc. reported revenue of $0, 100.0% lower than a year earlier, according to its SEC filings.
Who are Benitec Biopharma Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Montanova Capital, LLC, Nantahala Capital Management, LLC and Jupiter Topco LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Benitec Biopharma Inc.'s market cap?
On June 28, 2024, Benitec Biopharma Inc.'s market capitalisation was about $128M and net debt of -$50.9M. Market figures come from third-party market data and may be delayed.
Are insiders buying or selling Benitec Biopharma Inc. stock?
Over the last 12 months, Benitec Biopharma Inc.'s directors and officers reported 14 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Benitec Biopharma Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Benitec Biopharma Inc. announces its own schedule.